Comparative Molecular Dynamics Analyses on Pik3ca Hotspot Mutations With Pi3k Alpha Specific Inhibitors and Atp

dc.contributor.author Mentes, Muratcan
dc.contributor.author Karakuzulu, Basak Buse
dc.contributor.author Ucar, Gonlum Bahar
dc.contributor.author Yandim, Cihangir
dc.date.accessioned 2023-06-16T12:59:08Z
dc.date.available 2023-06-16T12:59:08Z
dc.date.issued 2022
dc.description.abstract PI3K pathway is heavily emphasized in cancer where PIK3CA, which encodes for the p110 alpha subunit of PI3K alpha, presents itself as the second most common mutated gene. A lot of effort has been put in developing PI3K in-hibitors, opening promising avenues for the treatment of cancer. Among these, PI3K alpha specific inhibitor alpelisib was approved by FDA for breast cancer and other alpha-isoform specific inhibitors such as inavolisib and serabelisib reached clinical trials. However, the mode of action of these inhibitors on mutated PI3K alpha and how they interact with mutant structures has not been fully elucidated yet. In this study, we are revealing the calculated in-teractions and binding affinities of these inhibitors within the context of PIK3CA hotspot mutations (E542K, E545K and H1047R) by employing molecular dynamics (MD) simulations. We performed principal component analysis to understand the motions of the protein complex during our simulations and also checked the correlated motions of all amino acids. Binding affinity calculations with MM-PBSA confirmed the consistent binding of alpelisib across mutations and revealed relatively higher affinities for inavolisib towards wild-type and H1047R mutant structures in comparison to other inhibitors. On the other hand, E542K mutation significantly impaired the interaction of inavolisib and serabelisib with PI3K alpha. We also investigated the structural relationship of the natural ligand ATP with PI3K alpha, and interestingly realized a significant reduction in binding affinity for the mutants, with potentially unexpected implications on the mechanisms that render these mutations oncogenic. Moreover, correlated motions of all residues were generally higher for ATP except the H1047R mutation which exhibited a distinguishable reduction. The results presented here could be guiding for pre-clinical and clinical studies of personalized medicine where individual mutations are a strong consideration point. en_US
dc.description.sponsorship Scientific and Technological Research Council of Turkey (TUBITAK) [2209A] en_US
dc.description.sponsorship This study was funded by the 2209A program of The Scientific and Technological Research Council of Turkey (TUBITAK) . en_US
dc.identifier.doi 10.1016/j.compbiolchem.2022.107726
dc.identifier.issn 1476-9271
dc.identifier.issn 1476-928X
dc.identifier.scopus 2-s2.0-85134431061
dc.identifier.uri https://doi.org/10.1016/j.compbiolchem.2022.107726
dc.identifier.uri https://hdl.handle.net/20.500.14365/1141
dc.language.iso en en_US
dc.publisher Elsevier Sci Ltd en_US
dc.relation.ispartof Computatıonal Bıology And Chemıstry en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject PIK3CA en_US
dc.subject PI3K en_US
dc.subject H1047R en_US
dc.subject E545K en_US
dc.subject E542K en_US
dc.subject Alpelisib en_US
dc.subject Serabelisib en_US
dc.subject Inavolisib en_US
dc.subject Moleculardynamics en_US
dc.subject ATP en_US
dc.subject Kinase Domain en_US
dc.subject P110-Alpha en_US
dc.subject Docking en_US
dc.subject Cancer en_US
dc.subject Recognition en_US
dc.subject Nvp-Byl719 en_US
dc.subject Alpelisib en_US
dc.title Comparative Molecular Dynamics Analyses on Pik3ca Hotspot Mutations With Pi3k Alpha Specific Inhibitors and Atp en_US
dc.type Article en_US
dspace.entity.type Publication
gdc.author.id YANDIM, Cihangir/0000-0002-2050-6186
gdc.author.scopusid 57809642600
gdc.author.scopusid 57809786200
gdc.author.scopusid 57809680000
gdc.author.scopusid 36474168400
gdc.author.wosid YANDIM, Cihangir/AAA-2250-2021
gdc.bip.impulseclass C4
gdc.bip.influenceclass C5
gdc.bip.popularityclass C4
gdc.coar.access metadata only access
gdc.coar.type text::journal::journal article
gdc.collaboration.industrial false
gdc.description.department İzmir Ekonomi Üniversitesi en_US
gdc.description.departmenttemp [Mentes, Muratcan; Karakuzulu, Basak Buse; Ucar, Gonlum Bahar; Yandim, Cihangir] Izmir Univ Econ, Fac Engn, Dept Genet & Bioengn, TR-35330 Izmir, Turkey; [Yandim, Cihangir] Dokuz Eylul Univ, Izmir Biomed & Genome Ctr IBG, Hlth Campus, TR-35340 Izmir, Turkey en_US
gdc.description.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
gdc.description.scopusquality Q3
gdc.description.volume 99 en_US
gdc.description.wosquality Q1
gdc.identifier.openalex W4284977327
gdc.identifier.pmid 35842959
gdc.identifier.wos WOS:000861782100002
gdc.index.type WoS
gdc.index.type Scopus
gdc.index.type PubMed
gdc.oaire.diamondjournal false
gdc.oaire.impulse 5.0
gdc.oaire.influence 2.6307208E-9
gdc.oaire.isgreen true
gdc.oaire.keywords Phosphatidylinositol 3-Kinases
gdc.oaire.keywords Adenosine Triphosphate
gdc.oaire.keywords Class I Phosphatidylinositol 3-Kinases
gdc.oaire.keywords Mutation
gdc.oaire.keywords Humans
gdc.oaire.keywords Breast Neoplasms
gdc.oaire.keywords Female
gdc.oaire.keywords Molecular Dynamics Simulation
gdc.oaire.keywords Protein Kinase Inhibitors
gdc.oaire.popularity 5.547797E-9
gdc.oaire.publicfunded false
gdc.oaire.sciencefields 0301 basic medicine
gdc.oaire.sciencefields 0303 health sciences
gdc.oaire.sciencefields 03 medical and health sciences
gdc.openalex.collaboration National
gdc.openalex.fwci 0.6946
gdc.openalex.normalizedpercentile 0.67
gdc.opencitations.count 3
gdc.plumx.crossrefcites 6
gdc.plumx.mendeley 20
gdc.plumx.pubmedcites 4
gdc.plumx.scopuscites 8
gdc.scopus.citedcount 9
gdc.virtual.author Yandım, Cihangir
gdc.wos.citedcount 9
relation.isAuthorOfPublication dcc90be4-1500-42cd-856d-16623e9ec3da
relation.isAuthorOfPublication.latestForDiscovery dcc90be4-1500-42cd-856d-16623e9ec3da
relation.isOrgUnitOfPublication ea0c3216-9cb2-4b28-8b85-9cf129e0036d
relation.isOrgUnitOfPublication 26a7372c-1a5e-42d9-90b6-a3f7d14cad44
relation.isOrgUnitOfPublication e9e77e3e-bc94-40a7-9b24-b807b2cd0319
relation.isOrgUnitOfPublication.latestForDiscovery ea0c3216-9cb2-4b28-8b85-9cf129e0036d

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
157.pdf
Size:
18.98 MB
Format:
Adobe Portable Document Format